Track
:
Track 04: Nonclinical and Translational Development/Early Phase Clinical Development
Program Code:
204
Date:
Tuesday, June 26, 2012
Time:
8:00 AM to 9:30 AM
EST
CHAIR
:
Barry Mangum, Duke University Medical Center, United States
He has an extensive background in neonatal and pediatric pharmacology and is the co-author and co-publisher of the leading drug dosing manual, NeoFax. He has represented the interest of pediatric patients by chairing and speaking at on the topic of neonatal pharmacology and legislative issues.
PRESENTER
(S):
Jeffrey Yap, Dana-Farber Cancer Institute, United States
Dr. Jeffrey Yap received his PhD in Medical Physics at the University of Chicago. He is the Senior Diagnostic Physicist at the Dana-Farber Cancer Institute and an Assistant Professor of Radiology at Harvard Medical School. He chairs the trial design committee in the SNM Clinical Trial Network.
Aamir Shahzad, International Society For Translational Medicine (ISTM), Austria
Currently based in Vienna, Austria, Prof. Shahzad is serving as a Secretary G and director of administration for ‘International Society For Translational Medicine’. He is serving as editor-in-chief for ‘Translational Biomedicine’ Journal.
Robert Kochan, Covance Clinical Development Services, United States
Dr. Kochan joined Covance in 1991 from academia (Univ. Wisc. Madison-exercise biochemistry) serving the Clinical Pharmacology group as its US Radiation Safety Officer and providing perspective Study Sponsors with regulatory and study requirements for conducting Phase I human AME studies in the US
Description
Developing techniques to better understand the adsorption, distribution, metabolism and excretion (ADME) of novel investigational compounds presents unique challenges for the clinical research facility, academic or nonacademic, as well as the pharmaceutical industry. In this symposium, three differing approaches to examining the use of radio-labeled compounds will be explored. These different aspects of imaging technology are highly desirable tools in understanding drug mechanisms of action and deposition within either tumor spaces or other sites of action.
Learning Objectives: Explain three benefits of using quantitative PET for measuring glucose utilization, metabolism and cell proliferation in clinical trials Describe the 14-C IV dose compounding requirements in performing microtracer absolute bioavailability study using AMS Describe the potential benefits of fluorescence correlation spectroscopy (FCS) as an alternative biomarker detection technique.